First report demonstrating the safety and immunogenicity of the SARS-COV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, observer-blind Phase I study
Research Square (2021) - Comments
doi: 10.21203/rs.3.rs-137265/v1 

Fengcai Zhu, Jingxin Li, Aimin Hui, Xiang Zhang, Yumei Yang, Rong Tang, Huayue Ye, Ruiru Ji, Mei Lin, Zhongkui Zhu, Özlem Türeci, Siyue Jia, Hongxing Pan, Fuzhong Peng, Zhilong Ma, Zhenggang Wu, Yunfeng Shi, Martin Bexon, Ugur Sahin, Li Zhu